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tries use the European Directive (ED) 2001/20/EC to govern all
research (e.g. Germany regional EC), others are in an “evolving
process” of coming into “adapted” compliance with the ED (e.g.
France); and others have their own independent regulations that
are less accessible (e.g. Saudi Arabia). Each country has varying
data protection legislation. CONCLUSIONS: For some, regula-
tory approvals are believed to be easier to acquire from disparate
regulatory bodies when no intervention is under study. However,
investigators cautioned that their various regulatory authorities
do not support natural history studies if they appear to be “large
cheap databases” driven by outside countries. More support for
such studies is likely if the natural history data serves as an
untreated control arm when treatments begin to be tested.
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OBJECTIVES: To investigate the relationship between differing
assumptions regarding the basis of placebo effects and estimates
of cost-effectiveness in non-linear models. METHODS:
Responses to placebos observed in randomized controlled trials
have a variety of mechanisms including: a “subject-expectancy”
effect speciﬁc to the experimental situation; a “subject-
expectancy” effect generalisable to a clinical situation; and a
“regression to the mean” effect arising from natural variation. If
the placebo response in a trial with placebo and active treatment
responses of RPLCB and RTX arose from a trial speciﬁc “subject-
expectancy”, we would expect to see no response to placebo and
RTX—RPLCB response to treatment in a clinical situation. If the
placebo response arose from generalisable “subject-expectancy”
or natural variation, we would expect to see RPLCB response to
placebo and RTX response to treatment in a clinical situation.
Estimates of cost-effectiveness from a simple model of an
epilepsy treatment, where the expected costs and effects were
non-linear with respect to response rate, were obtained under
these differing assumptions. RESULTS: The icer assuming a trial
speciﬁc “subject-expectancy” was ≤14,000 and assuming a
general “subject-expectancy” or natural variation placebo effect
was ≤20,000. CONCLUSIONS: For non-linear models the 
incremental cost-effectiveness ratios and the identiﬁcation of
optimum treatment choice may be sensitive to assumptions
regarding the placebo response mechanism. Even where the
analysis is based on the results of actively controlled trials,
responses may still include an element of placebo effect and the
incremental cost-effectiveness ratios may be sensitive to assump-
tions regarding the basis of this effect. We should also consider
that the placebo effect may differ over different dimensions of
response, such as initial probability and duration, and also care-
fully consider the appropriate estimation of the “no-treatment”
comparator response rates in clinical situations where the use of
placebos is not permissible.
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OBJECTIVES: Despite evidence on the cost-effectiveness of clin-
ical guidelines, patients and health care providers do not adhere
to guideline recommendations. Implementation strategies aim to
change guideline adherence but cost money to enact. As health
care resources are limited, it becomes increasingly important to
determine whether investing in guideline implementation is
worthwhile. METHODS: We developed a model to calculate the
total net monetary beneﬁts of guideline implementation for an
eligible patient population. By combining evidence on guidelines,
current practice and implementation strategies our model allows
the determination of the total potential to invest in guideline
implementation and the mutual comparison of implementation
strategies. We illustrated the use of our model with a hypothet-
ical example and examined the extent to which alternative mod-
elling assumptions inﬂuence the efﬁcient allocation of scarce
resources. RESULTS: Through illustration of the use; our model,
we demonstrated the inﬂuence of the threshold value ë, the base-
line guideline adherence and the patient population size on the
total guideline implementation investment potential and the total
net monetary beneﬁts of guideline implementation. CONCLU-
SIONS: Using a total net monetary beneﬁts approach, our model
overcomes problems with the use of policy cost-effectiveness
ratios and allows the incorporation of uncertainty surrounding
evidence on guidelines, current practice and implementation
strategies. Moreover, our model provides simple and useful tool
to examine the value for money of guideline implementation and
inform policy decisions about efﬁcient allocation of scarce
resources.
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OBJECTIVE: To explore the deﬁnition of therapeutic compli-
ance and evaluate the most common factors causing therapeutic
non-compliance. METHODS: A qualitative review was under-
taken by a literature search of the Medline database from 1970
to 2005. The following key words were used: treatment refusal,
patient compliance, patient dropouts, factors, predictors and
determinants. RESULTS: A total of 7372 articles were retrieved
by the literature review process. From the literature review, the
most commonly accepted deﬁnition of therapeutic compliance is
patient’s behaviors (in terms of taking medication, following
diets, or executing life style changes) coincide with health care
providers’ recommendation for health and medical advice. 
The preliminary evaluation revealed a number of factors that
contributed to therapeutic noncompliance. These factors
include:Patient-centered factors: demographic factors (age,
gender, ethnicity, education background , marriage status ),
patients’ beliefs, motivation and attitude about The rapy, patient-
prescriber relationship, health literacy, patients’ education, phys-
ical difﬁculties, smoking and alcohol intake, poor quality of life,
forgetfulness, a history of noncompliance.Therapy-related
factors: treatment complexity, duration of the treatment period,
medication side effects, degree of behavioral change required.
Social and economic factors: cost, income, social support, health
care system factors, and characteristics of the disease. Broadly
speaking, factors related to poor therapeutic compliance can be
categorized to intentional factors and non-intentional factors.
They are complicated and not fully predictive. CONCLUSION:
From the review, it would appear that there are numerous studies
on the issue of therapeutic noncompliance, the deﬁnition of ther-
apeutic compliance is adequately addressed and generally
accepted by the clinical communities. Regarding reasons for ther-
apeutic non-compliance, there are many factors being reported
and studied over the years, but the evidence is sometimes con-
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tradictory and variable except a few important issues. From the
perspective of clinical health care delivery, therapeutic noncom-
pliance remains a major problem in enhancing health care 
outcomes.
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OBJECTIVES: A new utility index derived of the SF-36, the SF-
6D, was recently developed and has generated an increasing
research in different groups of patients and has also been com-
pared with other utility measures, as it is the EQ-5D. The
purpose of present work was to evaluate the differences between
the weighted and not weighted version of two utility measures:
the Spanish SF-6D and EQ-5D. METHODS: A total of 1843
complete measures of the SF-36 and the EQ-5D (5 items and
visual analogic scale-VAS) from 1283 patients who received a
solid organ transplant (kidney, liver, heart or lung) were used.
Data were collected at different moments during the ﬁrst year
after the surgery in the context of the Spanish Research Network
on Transplantation. SF-6D values were calculated using the
model proposed by its creator (weighted version) and without
tariff values, as has been proposed by some authors (not
weighted). EQ-5D values were calculated using Spanish VAS
tariff (VAS-t), the time-trade off tariff (TTO-t) and also without
tariff values (not weighted). Spearman correlation coefﬁcients
were calculated between SF-6D (weighted and not weighted) and
EQ-5D values (VAS-t, TTO-t and not weighted). RESULTS:
Mean value of weighted SF-6D was 0.67 (0.15) and not
weighted, 0.72 (0.15). Mean values of EQ-5D VAS-t was 0.69
(0.24), of TTO-t, 0.70 (0.32) and of not weighted EQ-5D, 0.63
(0.33). SF-6D values had moderate correlation with EQ-5D VAS-
t (r = 0.734) and EQ-5D TTO-t (r = 0.731) (both p < 0.001).
Using the SF-6D index without tariff values, it had a high cor-
relation with the weighted version of SF-6D (r = 0.969, p <
0.001), and moderate with the EQ-5D VAS-t (r = 0.754), EQ-
5D TTO-t (r = 0.750) and no weighted EQ-5D (r = 0.784) (p <
0.001). CONCLUSIONS: The efforts made to get the prefer-
ences values and calculate the weights in utility indexes do not
seem to add enough information to make them worthy.
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OBJECTIVES: It is well recognised that electronic data capture
(EDC) is revolutionising the data collection and management of
clinical trials data especially for pre-registration Phase I to III
studies. We will discuss the beneﬁts of the use of EDC for patient
reported outcomes and especially within the context of large
observational studies. METHODS: Using EDC, patient reported
outcome data are collected directly by the patient onto the data
capture device; this can be either a tablet pc at the study site or
using a PDA for diary data. Whilst the patient is entering data,
the device will prompt them if they do not ﬁll in the question-
naire correctly or do not complete particular questions.
RESULTS: Even this simple interaction with the patient of ensur-
ing the answer provided is the most appropriate one improves
the quality of the patient reported outcome data. For example,
the query rate for these data is usually reduced from 6 to 10 fold
compared with paper CRF collection and of course for patient
reported data these queries usually cannot be updated so that
these data remain inconsistent and of poorer quality. Other ben-
eﬁts include the on-line reporting of data which is especially ben-
eﬁcial for observational studies of moderate to long duration.
Often several statistical reports are made from these data for
example by conducting interims for baseline data, 3-month, 6-
month, and 1-year data, etc. These reports were often produced
several months after the last data were collected due to the delay
between data processing of paper CRF data and the processes
involve with statistical reporting. CONCLUSIONS: Now it is
possible to provide near real-time access to reports via EDC
working with a suite of pre-validated statistical programs. These
can be produced on an on-going basis, for example we can
update our reports daily.
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OBJECTIVE: Conduct a systematic review of the literature on
delayed-action dose preparation compared to regular dose
preparation, and to examine the impact of a change in dose fre-
quency on compliance and health outcomes (e.g., health-related
quality of life, patient satisfaction, treatment costs), as well 
as efﬁcacy and tolerability proﬁle. METHODS: The medical lit-
erature databases MEDLINE and Cochrane Library were
reviewed from 1966 through 2006 for published, peer-reviewed
articles. Search terms were combinations of “delayed-action
preparations”, “dose frequency”, “dose administration sched-
ule”, “dosing” and “efﬁcacy”, “safety”, “clinical effectiveness”,
“preferences”, “adherence”, “compliance”, “persistence”,
“health-related quality of life”, “patient satisfaction”, “resource
use”, and “costs”. References from identiﬁed articles were not
used to expand the search. Two reviewers independently
reviewed titles, abstracts, and ﬁnally full-text articles. A total of
57 peer-review articles were selected for the full-text review,
including 14 literature/systematic reviews and 2 meta-analysis
articles. RESULTS: All of the clinical studies, except 2, support
better or comparable efﬁcacy when using a simple dose (e.g.,
weekly dose vs. multiple doses per week or once-daily versus
twice-daily or three-times-daily) to treat clinical symptoms in the
following disease areas: cardiovascular disorders, diabetes, neu-
rological/psychological disorders, rheumatoid/muscle disorders,
nephrology/urology disorders. Along with literature/systematic
reviews and meta-analysis articles, these studies have supported
the general advantages of reducing dosing frequency on
improved compliance (16 studies), improved quality of life or
patient satisfaction (8 studies), greater control over side effects
(3 studies), and improved economic outcomes using extended-
release formulation (2 studies). CONCLUSION: In general,
reducing dose frequency by using a delayed-action dose may
offer beneﬁts for patients in terms of improving medication com-
pliance, effectiveness and adverse effect proﬁles, while possibly
reducing health care costs. However, physicians and patients
need to bear in mind that the wide variety of delivery systems
are available to ﬁnd the most appropriate one for a particular
patient.
